These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 11319914)

  • 1. Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1.
    Maijgren-Steffensson C; Sönnerborg A; Vahlne A; Britton S; Larsson S; Ahrlund-Richter L
    Mol Ther; 2001 Apr; 3(4):531-5. PubMed ID: 11319914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
    Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel ribozyme target site located in the HIV-1 nef open reading frame.
    Larsson S; Hotchkiss G; Su J; Kebede T; Andäng M; Nyholm T; Johansson B; Sönnerborg A; Vahlne A; Britton S; Ahrlund-Richter L
    Virology; 1996 May; 219(1):161-9. PubMed ID: 8623525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obstacles to successful antiretroviral treatment of HIV-1 infection: problems & perspectives.
    Potter SJ; Chew CB; Steain M; Dwyer DE; Saksena NK
    Indian J Med Res; 2004 Jun; 119(6):217-37. PubMed ID: 15243161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
    Puthanakit T; Oberdorfer A; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2005 Jul; 41(1):100-7. PubMed ID: 15937769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
    Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
    Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
    Miró JM; Manzardo C; Pich J; Domingo P; Ferrer E; Arribas JR; Ribera E; Arrizabalaga J; Loncá M; Cruceta A; de Lazzari E; Fuster M; Podzamczer D; Plana M; Gatell JM;
    AIDS Res Hum Retroviruses; 2010 Jul; 26(7):747-57. PubMed ID: 20624069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
    Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM
    Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).
    Djabarouti S; Breilh D; Pellegrin I; Lavit M; Camou F; Caubet O; Fleury H; Saux MC; Pellegrin JL
    J Antimicrob Chemother; 2006 Nov; 58(5):1090-3. PubMed ID: 16921181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
    Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N
    Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
    Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of anti-HIV-1 drugs.
    Lu XF; Chen ZW
    Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.